[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Abe K, Wakatsuki T, Katsushima F, Monoe K, Kanno Y, Takahashi A, Yokokawa J, Ohira H: A case of advanced intrahepatic cholangiocarcinoma successfully treated with chemosensitivity test-guided systemic chemotherapy. World J Gastroenterol; 2009 Nov 7;15(41):5228-31
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of advanced intrahepatic cholangiocarcinoma successfully treated with chemosensitivity test-guided systemic chemotherapy.
  • Intrahepatic cholangiocarcinoma (ICC) is a relatively rare and highly fatal neoplasm that arises from the biliary epithelium.
  • Here we present a case of advanced ICC successfully treated by chemosensitivity test-guided systemic chemotherapy combining S-1 and cisplatin (CDDP).
  • Abdominal ultrasonography and computed tomography (CT) showed low-density masses of 50 and 15 mm in diameter, respectively in segment VIII of the liver and in the enlarged lymph node in the para-aorta.
  • Since the patient was inoperable for lymph node metastasis, she underwent systemic chemotherapy with gemcitabine.
  • Six months after initiation of chemotherapy, CT revealed ICC progression in the liver and pleural dissemination with pleural effusion.
  • The patient was admitted to our hospital for anticancer drug sensitivity testing on June 9, 2008.
  • Based on the sensitivity test results, we elected to administer systemic chemotherapy combining S-1 and CDDP.
  • Two months into the second chemotherapy treatment, CT revealed a reduction of the tumors in the liver and lymph node and a decrease in pleural effusion.
  • After eight cycles of the second chemotherapy, 17 mo after ICC diagnosis, she is alive and well with no sign of recurrence.
  • We conclude that chemosensitivity testing may effectively determine the appropriate chemotherapy regimen for advanced ICC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic. Cholangiocarcinoma / drug therapy. Drug Therapy / methods
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Combinations. Female. Humans. Oxonic Acid / administration & dosage. Tegafur / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 The WJG Press and Baishideng. All rights reserved.
  • [Cites] Hepatogastroenterology. 1996 Sep-Oct;43(11):1159-64 [8908545.001]
  • [Cites] Ann Oncol. 1996 Aug;7(6):593-600 [8879373.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5276-82 [7585588.001]
  • [Cites] Mayo Clin Proc. 1995 May;70(5):425-9 [7537346.001]
  • [Cites] J Immunol Methods. 1993 Mar 15;160(1):81-8 [7680699.001]
  • [Cites] Br J Cancer. 1992 Nov;66(5):794-9 [1419622.001]
  • [Cites] J Surg Oncol. 1991 Nov;48(3):188-93 [1943116.001]
  • [Cites] Cancer Res. 1987 Feb 15;47(4):943-6 [3802101.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Dec;83(23):8923-5 [3466165.001]
  • [Cites] Med Biol. 1984;62(6):338-43 [6543460.001]
  • [Cites] Invest New Drugs. 2004 Apr;22(2):193-8 [14739669.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):507-17; discussion 517-9 [11573044.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):183-6 [11300321.001]
  • [Cites] Anticancer Res. 2000 Jul-Aug;20(4):2389-92 [10953301.001]
  • [Cites] Eur J Cancer. 1997 May;33(6):960-6 [9291821.001]
  • [Cites] Oncologist. 2008 Apr;13(4):415-23 [18448556.001]
  • [Cites] Chin Med Sci J. 2008 Mar;23(1):54-9 [18437912.001]
  • [Cites] Ann Oncol. 2008 Jan;19(1):99-103 [17846018.001]
  • [Cites] Curr Opin Gastroenterol. 2007 May;23(3):317-23 [17414849.001]
  • [Cites] Br J Cancer. 2006 Aug 21;95(4):532-40 [16868542.001]
  • [Cites] Hepatology. 2005 Jan;41(1):5-15 [15690474.001]
  • [Cites] Br J Cancer. 2004 Nov 15;91(10):1769-74 [15505626.001]
  • (PMID = 19891026.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2773906
  •  go-up   go-down


2. Matsuzaki M, Nakano M, Komatsu H, Ohashi K: [Aortic replacement during post chemotherapy retroperitoneal residual tumor resection for nonseminomatous germ cell tumor: a case report]. Hinyokika Kiyo; 2005 Dec;51(12):831-4
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Aortic replacement during post chemotherapy retroperitoneal residual tumor resection for nonseminomatous germ cell tumor: a case report].
  • A large hard mass was palpable in the abdominal cavity.
  • Abdominal computed tomography revealed large retroperitoneal cystic tumors.
  • Under the diagnosis of testicular tumor and retroperitoneal lymph node metastasis, left radical orchiectomy was performed and the histopathological examination showed mature teratoma.
  • He received three cycles of chemotherapy with bleomycin, etoposide, and cisplatin and we performed retroperitoneal residual tumor resection.
  • Because the tumor tightly adhered to the aortic wall, abdominal aorta was resected and replaced by an artificial vessel.
  • Histopathological diagnosis was cystopapillary adenocarcinoma and mature teratoma.
  • [MeSH-major] Adenocarcinoma, Papillary / surgery. Aorta, Abdominal / surgery. Lymph Node Excision. Lymph Nodes / pathology. Neoplasms, Multiple Primary. Teratoma / surgery. Testicular Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Etoposide / administration & dosage. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm, Residual / surgery. Orchiectomy. Retroperitoneal Space. Tissue Adhesions

  • Genetic Alliance. consumer health - Nonseminomatous germ cell tumor.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440734.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


3. Jerius JT, Elmajian DA, Rimmer DM, Spires KS: Floppy aortic graft reconstruction for germ cell tumor invasion of the infrarenal aorta. J Vasc Surg; 2003 Apr;37(4):889-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Floppy aortic graft reconstruction for germ cell tumor invasion of the infrarenal aorta.
  • We describe a new approach of intraoperative floppy aortic graft reconstruction in a young patient with testicular germ cell cancer in whom a 14 cm pseudoaneurysm involving the infrarenal aorta developed after four courses of preoperative chemotherapy.
  • This technique prevents significant lower extremity and pelvic ischemia during resection of the aorta and retroperitoneal tumor while providing the urologic surgeon with excellent exposure and minimal interference from the aortic graft.
  • [MeSH-major] Aneurysm, False / etiology. Aneurysm, False / surgery. Aorta, Abdominal / surgery. Blood Vessel Prosthesis Implantation / methods. Germinoma / pathology. Germinoma / surgery. Testicular Neoplasms / pathology. Vascular Neoplasms / secondary. Vascular Neoplasms / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Male. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Staging. Reoperation

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Vasc Surg. 2004 Apr;39(4):922; author reply 922 [15074311.001]
  • (PMID = 12663994.001).
  • [ISSN] 0741-5214
  • [Journal-full-title] Journal of vascular surgery
  • [ISO-abbreviation] J. Vasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Matsunuma H, Ono Y, Hattori R, Gotoh M, Yoshino Y, Ohshima S: [Laparoscopic retroperitoneal lymphnode dissection for testicular cancer: Nagoya experience]. Hinyokika Kiyo; 2003 Jul;49(7):377-80
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was placed in a semilateral position and 5 trocars were introduced through the lateral abdominal wall.
  • After incising the peritoneum along the Toldt line, the colon was reflected medially and the retroperitoneal structures such as the ureter, aorta, inferior vena cava and both renal arteries and veins were exposed.
  • The procedure was completed successfully on all 6 patients.
  • The average operative time was 3.4 hours for 3 patients with stage I disease and 4.4 hours for 3 patients with stage III disease treated with prior chemotherapy.
  • [MeSH-minor] Adult. Humans. Lymph Nodes / pathology. Male. Neoplasm Staging. Retroperitoneal Space

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12968476.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Strecker EP, Heber R, Boos I, Göttmann D, Heinrich D: Preliminary experience with locoregional intraarterial chemotherapy of uterine cervical or endometrial cancer using the peripheral implantable port system (PIPS): a feasibility study. Cardiovasc Intervent Radiol; 2003 Mar-Apr;26(2):118-22
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary experience with locoregional intraarterial chemotherapy of uterine cervical or endometrial cancer using the peripheral implantable port system (PIPS): a feasibility study.
  • The purpose of this study was to assess the suitability of a percutaneously implantable catheter port system (PIPS) for repeated intraarterial locoregional chemotherapy (ILC) for cervical and endometrial carcinoma.
  • In 30 patients with advanced, recurrent, or high-risk cervical (n = 23) or endometrial (n = 7) carcinoma, PIPS for ILC was implanted via a femoral access, the catheter localized in the infrarenal abdominal aorta.
  • Chemotherapy was performed adjuvantly after surgery (n = 14) or neo-adjuvantly to enable surgery, or for palliation (n = 16).
  • At 2 years follow-up, complete remission was observed in 7/14 patients with adjuvant chemotherapy, partial remission in 3/14.
  • Successful down-staging could be achieved in 4/8 patients with neo-adjuvant chemotherapy.
  • The PIPS is suitable for repeated ILC which may be a valuable method for pre- and post-surgical therapy of advanced or high-risk cervical and endometrial cancer, for adjuvant chemotherapy as well as neo-adjuvantly for down-staging, or for palliation.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / therapy. Infusion Pumps, Implantable. Uterine Cervical Neoplasms / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Adult. Aorta, Abdominal / radiography. Aorta, Abdominal / surgery. Catheters, Indwelling / adverse effects. Disease Progression. Equipment Design. Equipment Safety. Feasibility Studies. Female. Femoral Artery / radiography. Femoral Artery / surgery. Fibrinolytic Agents / therapeutic use. Follow-Up Studies. Humans. Iliac Artery / radiography. Iliac Artery / surgery. Infusions, Intra-Arterial / instrumentation. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / therapy. Postoperative Complications / etiology. Postoperative Complications / mortality. Survival Analysis. Thrombosis / drug therapy. Thrombosis / etiology. Time Factors. Tissue Plasminogen Activator / therapeutic use. Treatment Outcome. Vascular Surgical Procedures. Women's Health


6. Nomura E, Niki M, Fujii K, Shinohara H, Nishiguchi K, Sonoda T, Tanigawa N: Efficacy of intraperitoneal and intravenous chemotherapy and left upper abdominal evisceration for advanced gastric cancer. Gastric Cancer; 2001;4(2):75-82
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of intraperitoneal and intravenous chemotherapy and left upper abdominal evisceration for advanced gastric cancer.
  • BACKGROUND: The study was carried out to evaluate the efficacy of intraperitoneal (i.p.) and intravenous (i.v.) chemotherapy, as well as left upper abdominal evisceration (LUAE), for patients with advanced gastric cancer.
  • METHODS: We carried out a retrospective study of 348 patients who underwent gastrectomy for advanced gastric carcinoma between 1978 and 1998 at our institution and who had macroscopic type 3 or 4 cancer (Japanese classification) with depth of invasion to the serosal surface, but no liver metastasis or lymph node metastasis around the abdominal aorta.
  • (1) intraoperative i.p. chemotherapy alone, (2) postoperative i.v. chemotherapy alone, (3) both i.p. and i.v., or (4) no chemotherapy.
  • In P+ patients, survival was compared between those who received i.v. chemotherapy and those who did not, and between those who received i.p. chemotherapy and those who did not.
  • RESULTS: For P- patients, there was no survival advantage with adjuvant i.p. or i.v. therapy when compared with surgery alone.
  • In P+ patients aged less than 60 years, there was improvement in survival for those who underwent i.p. therapy together with surgery (P < 0.05), but not for those who had i.v. chemotherapy after surgery.
  • When LUAE was examined, there was a survival advantage for this procedure when there was no peritoneal dissemination.
  • Three of the 4 patients were aged less than 60 years, and all 4 had macroscopic type 4 gastric cancers.
  • CONCLUSION: Although the prognosis for patients with invasive type gastric cancer remains poor, there have been a few long-term survivors, in whom this survival was associated with aggressive combination therapy, including surgery, i.p., and i.v. therapy.
  • P+ patients aged less than 60 years and patients with type 4 gastric cancer may stand to benefit most from such therapy.
  • For P- patients, the role of adjuvant i.p. or i.v. therapy continues to be ambiguous, although LUAE in this population may be superior to PS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / surgery. Gastrectomy. Peritoneal Neoplasms / surgery. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Chemotherapy, Adjuvant. Female. Humans. Infusions, Parenteral. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11706764.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Tanaka H, Kondo E, Kawato H, Kikukawa T, Toyoda N: Aortitis during intraarterial chemotherapy for cervical cancer. Int J Clin Oncol; 2002 Feb;7(1):62-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aortitis during intraarterial chemotherapy for cervical cancer.
  • A 76-year-old woman with stage IIb cervical cancer with a bulky tumor experienced aortitis during continuous intraarterial cisplatin-based chemotherapy.
  • The chemotherapy was administered through a catheter tip placed in the aorta abdominalis, utilizing an external infusion pump.
  • During the third course of chemotherapy, she complained of left-sided lower back pain and moderate fever was observed.
  • Elevated white blood cell count (WBC) and C-reactive protein (CRP) level were noted, and an abdominal X-ray and urgent computed tomography (CT) were performed.
  • At this level of the aortic wall, soft tissue density surrounded the aorta completely.
  • Aortitis caused by the intraarterial chemotherapy, was strongly suspected.
  • It was thought that the maldistribution of drugs and changes in the drug flow occurred due to the vertebral height movement of the catheter tip against the aortic blood flow, and there, flow to the vasa vasorum may have occurred.
  • Chemical vasculitis of the vasa vasorum due to the anticancer drugs was strongly suspected as a contributing factor of the aortitis.
  • Because of the long-term use of an intraarterial catheter, the maldistribution of drugs and changes in the drug flow occurred physically and biologically during the course of the chemotherapy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Aortitis / diagnosis. Carcinoma, Squamous Cell / drug therapy. Catheterization / adverse effects. Cisplatin / administration & dosage. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Infusions, Intra-Arterial / adverse effects. Magnetic Resonance Imaging. Neoplasm Staging. Tomography, X-Ray Computed


8. Guzman R, Dubach-Schwizer S, Heini P, Lovblad KO, Kalbermatten D, Schroth G, Remonda L: Preoperative transarterial embolization of vertebral metastases. Eur Spine J; 2005 Apr;14(3):263-8
Hazardous Substances Data Bank. POLYVINYL ALCOHOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Aorta, Abdominal / drug effects. Embolization, Therapeutic / methods. Spinal Neoplasms / secondary. Spinal Neoplasms / therapy. Surgical Procedures, Operative / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lumbar Vertebrae / blood supply. Lumbar Vertebrae / pathology. Magnetic Resonance Angiography. Male. Middle Aged. Neoplasm Staging. Polyvinyl Alcohol / therapeutic use. Preoperative Care / methods. Radiology, Interventional. Retrospective Studies. Risk Assessment. Survival Analysis. Thoracic Vertebrae / blood supply. Thoracic Vertebrae / pathology. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2001 May;22(5):997-1003 [11337348.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1975 Nov;125(3):609-16 [1081841.001]
  • [Cites] Clin Orthop Relat Res. 1982 Sep;(169):95-102 [7105592.001]
  • [Cites] J Bone Joint Surg Am. 1985 Mar;67(3):375-82 [3882717.001]
  • [Cites] J Neurosurg. 1985 Nov;63(5):676-84 [4056870.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 May;20(5):757-63 [10369341.001]
  • [Cites] J Neurosurg. 1990 Oct;73(4):548-54 [2398386.001]
  • [Cites] Acta Orthop Scand. 1993 Feb;64(1):9-12 [8451959.001]
  • [Cites] Radiologe. 1995 Jan;35(1):55-9 [7534427.001]
  • [Cites] Cardiovasc Intervent Radiol. 1997 Sep-Oct;20(5):343-7 [9271643.001]
  • [Cites] Radiology. 1990 Sep;176(3):683-6 [2389026.001]
  • (PMID = 15378414.001).
  • [ISSN] 0940-6719
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 9002-89-5 / Polyvinyl Alcohol
  • [Other-IDs] NLM/ PMC3476739
  •  go-up   go-down


9. Gohongi T, Iida H, Nakai R, Gunji N, Orii K: [Concurrent low-dose cisplatin/5-FU chemotherapy and radiation for the recurrent gastric carcinoma--case reports]. Gan To Kagaku Ryoho; 2006 Jul;33(7):989-92
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Concurrent low-dose cisplatin/5-FU chemotherapy and radiation for the recurrent gastric carcinoma--case reports].
  • We report two postoperative cases of recurrent gastric carcinoma successfully treated with concurrent low-dose cisplatin/5-FU chemotherapy and radiation therapy.
  • Case 2: A 75-year-old man underwent total gastrectomy and splenectomy for advanced gastric carcinoma followed by multiple lymph node swelling along the abdominal aorta one year after surgery.
  • We employed concurrent radiation therapy and low-dose CDDP/5-FU therapy for the recurrent gastric carcinoma tumor which consisted of 5-FU (125-250 mg/body/day, as a 24-h intravenous injection for 4 weeks) and low-dose cisplatin (10 mg/body on day 1, 8, 15, 22).
  • X-ray radiation was delivered to the target tumor in a daily fraction of 1.8 Gy, 6 days/week, with a total dose of 50.4 Gy.
  • PR and CR were obtained after the therapy.
  • The concurrent low-dose cisplatin/5-FU chemotherapy and radiation therapy could be an effective treatment modality for the recurrent tumors of gastric carcinoma after surgery.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymph Nodes / pathology. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Fluorouracil / administration & dosage. Gastrectomy. Humans. Lymphatic Metastasis. Male. Radiotherapy Dosage. Splenectomy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16835494.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


10. Ho CM, Chien TY, Shih BY, Huang SH: Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma. Gynecol Oncol; 2003 Mar;88(3):394-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma.
  • OBJECTIVE: The aim was to determine the benefits of lymphadenectomy and paclitaxel plus carboplatin chemotherapy for stage I ovarian clear cell carcinoma (defined as intra-abdominal disease confined to the ovaries).
  • METHODS: Twenty patients with stage I pure clear cell carcinoma of the ovary diagnosed between 1991 and 2001 were divided into two groups: Group A (12 patients, 1997-2001) underwent complete surgical staging including bilateral salpingo-oophorectomy, hysterectomy, omentectomy, and pelvic and para-aortic lymphadenectomy, followed by paclitaxel and carboplatin chemotherapy.
  • Group B (8 patients, 1991-1996) underwent bilateral salpingo-oophorectomy, hysterectomy, and omentectomy without lymphadenectomy, followed by cisplatin-based chemotherapy.
  • The clinical characteristics of the two groups were similar, except for lymphadenectomy and regimen of chemotherapy.
  • Median time to recurrence was 8 months.
  • CONCLUSIONS: Complete surgical staging, including pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy, appeared to be capable of improving survival of patients with stage I ovarian clear cell carcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Aorta. Carboplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Lymph Node Excision. Lymph Nodes / pathology. Lymph Nodes / surgery. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Pelvis. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12648592.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


11. Hasegawa K, Matsumoto R, Yamada H, Kuroda T, Mamiya Y, Kon A: [A case of sigmoid colon carcinoma accompanied with hydronephrosis caused by peritoneal dissemination and para-aortic lymph node metastases markedly responded to chemotherapy]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2213-6
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of sigmoid colon carcinoma accompanied with hydronephrosis caused by peritoneal dissemination and para-aortic lymph node metastases markedly responded to chemotherapy].
  • He received chemotherapy with LV+5-FU in the middle of August, continuously with bevacizumab (BV)+mFOLFOX6 in the end of October.
  • In December, an elevated CEA marker was decreased after these treatments.
  • [MeSH-major] Hydronephrosis / etiology. Neoplasm Seeding. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / pathology
  • [MeSH-minor] Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aorta, Abdominal. Bevacizumab. Colostomy. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Lymphatic Metastasis. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Peritoneal Cavity

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037374.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 2S9ZZM9Q9V / Bevacizumab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


12. Matsumura H, Iwasaki Y, Ohashi M, Iwanaga T, Takahashi K, Yamaguchi T, Matsumoto H, Nakano D: [A case of advanced gastric cancer with paraaortic lymph node recurrence reaching a long-term survival by S-1 chemotherapy]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2284-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with paraaortic lymph node recurrence reaching a long-term survival by S-1 chemotherapy].
  • A 55-year-old male patient with epigastralgia was diagnosed as type 3 gastric cancer at the lower gastric region.
  • He was treated with 5'-DFUR and PSK therapy as adjuvant chemotherapy for 18 months after surgery.
  • At 24 months after the operation, paraaortic lymph node recurrence was confirmed by computed tomography.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Lymphatic Metastasis / pathology. Oxonic Acid / administration & dosage. Stomach Neoplasms / drug therapy. Tegafur / administration & dosage
  • [MeSH-minor] Aorta, Abdominal. Chemotherapy, Adjuvant. Drug Combinations. Humans. Male. Middle Aged. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037397.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


13. Nakamura K, Nakamura T, Kurachi K, Fukazawa A, Hayashi T, Nakajima A, Suzuki S, Konno H: [A case of sigmoid colon cancer with metastases of para-aortic lymph nodes treated with curative resection after irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy]. Gan To Kagaku Ryoho; 2008 Jun;35(6):1017-20
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of sigmoid colon cancer with metastases of para-aortic lymph nodes treated with curative resection after irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy].
  • A 54-year-old woman visited our hospital with a chief complaint of lower abdominal pain and melena.
  • Abdominal CT revealed metastases to para-aortic lymph node, so our diagnosis was unresectable sigmoid colon cancer.
  • Two weeks after surgery, she underwent a 1-week chemotherapy regimen (CPT-11 80 mg/m(2)/week+5-FU 2,000 mg/m(2)/week+l-LV 250 mg/m(2)/week) modified AIO regimen combined irinotecan for 3 weeks, followed by a 1-week rest interval as one course.
  • Throughout the period of treatment, there was no adverse event, and this regimen has been maintained for 5 courses.
  • After 5 courses of chemotherapy, primary tumor and metastases to para-aortic lymph nodes were remarkably reduced on colonoscopy and abdominal CT.
  • This combination therapy may well be useful for advanced colon cancer patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aorta / pathology. Camptothecin / analogs & derivatives. Fluorouracil / therapeutic use. Leucovorin / therapeutic use. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Metastasis / radiography. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633237.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


14. Hiura M, Nogawa T, Matsumoto T, Yokoyama T, Shiroyama Y, Wroblewski J: Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma. Int J Gynecol Cancer; 2010 Aug;20(6):1000-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma.
  • OBJECTIVE: The purposes of this study were to assess modified radical hysterectomy including systematic pelvic and para-aortic lymphadenectomy followed by adjuvant chemotherapy in patients with para-aortic lymph node (PAN) metastasis in endometrial carcinoma and to identify the multivariate independent prognostic factors for long-term survival during the past 10 years.
  • Patients with PLN metastasis received adjuvant chemotherapy, and adjuvant radiation was not part of our institutional protocol.
  • CONCLUSIONS: It is suggested that surgery with systematic pelvic and para-aortic lymphadenectomy followed by adjuvant chemotherapy could improve long-term survival in patients with PAN metastasis, although there are only 21 patients with PAN metastasis.
  • [MeSH-major] Carcinoma / mortality. Carcinoma / secondary. Chemotherapy, Adjuvant. Endometrial Neoplasms / mortality. Endometrial Neoplasms / therapy. Retroperitoneal Neoplasms / secondary. Retroperitoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Aorta, Abdominal. Biopsy, Needle. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Immunohistochemistry. Lymph Node Excision / methods. Lymph Nodes / pathology. Lymph Nodes / surgery. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Retroperitoneal Space. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20683408.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, Rotman M, Gershenson D, Mutch DG: Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol; 2004 Mar 1;22(5):872-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
  • RESULTS: The median follow-up time for 228 surviving patients was 6.6 years.
  • The rate of serious late complications of treatment was similar for the two treatment arms.
  • CONCLUSION: Mature analysis confirms that the addition of fluorouracil and cisplatin to radiotherapy significantly improved the survival rate of women with locally advanced cervical cancer without increasing the rate of late treatment-related side effects.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brachytherapy / methods. Neoplasm Invasiveness / pathology. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Aorta, Abdominal / radiation effects. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Dose-Response Relationship, Radiation. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Pelvis / radiation effects. Probability. Radiation Dosage. Reference Values. Risk Assessment. Survival Analysis. Treatment Outcome


16. Kikkawa F, Nawa A, Ino K, Shibata K, Kajiyama H, Nomura S: Advances in treatment of epithelial ovarian cancer. Nagoya J Med Sci; 2006 Jan;68(1-2):19-26
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in treatment of epithelial ovarian cancer.
  • Since most cases of epithelial ovarian cancer are advanced at diagnosis, this disease is one of the most lethal malignancies of the female genital tract.
  • In recent years, aggressive cytoreductive surgery and chemotherapy have been employed in an attempt to improve the survival rate in patients with epithelial ovarian cancer.
  • Introduction of platinum anticancer drugs increased survival rate, and several randomized studies have been tried to establish the better combination of anticancer drugs.
  • As a result, the combination of paclitaxel and carboplatin was considered as standard regimen for the first-line treatment of patients with advanced ovarian cancer.
  • Since International Federation of Gynecology and Obstetrics (FIGO) accepted a postoperative staging system in 1988, staging laparotomy needs hysterectomy, bilateral adnexectomy, omentectomy, and pelvic and para-aorta lymphadenectomy.
  • Complete resection of the tumor is often difficult since the disease has spread to the abdominal cavity.
  • In such cases, interval debulking surgery is performed after chemotherapy to remove tumors completely.
  • The effectiveness of neoadjuvant chemotherapy and interval debulking surgery still remains unclear.
  • This review will describe the advances in surgical procedures and chemotherapy in treatment of ovarian cancer patients.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / drug therapy. Neoplasms, Glandular and Epithelial / surgery. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Lymph Node Excision. Neoadjuvant Therapy. Neoplasm Staging. Ovariectomy. Prognosis. Randomized Controlled Trials as Topic. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16579172.001).
  • [ISSN] 0027-7622
  • [Journal-full-title] Nagoya journal of medical science
  • [ISO-abbreviation] Nagoya J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 24
  •  go-up   go-down


17. Wang X, Tangjitgamol S, Liu J, Kavanagh JJ: Response of recurrent uterine high-grade malignant mixed müllerian tumor to letrozole. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1243-8
Hazardous Substances Data Bank. LETROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite the use of multimodality treatments including surgery, chemotherapy, and radiotherapy, prognosis is still poor in most cases.
  • At the initial diagnosis of high-grade uterine MMMT in February 2001, the patient underwent total abdominal hysterectomy, bilateral salpingo-oophorectomy, and postoperative pelvic radiotherapy.
  • Two years later, an asymptomatic retroperitoneal mass was discovered on surveillance abdominal computed tomography scanning.
  • The 3.5- x 3.0-cm mass was considered inoperable owing to its location near the aorta at the level of the renal vessels.
  • The patient declined radiation or chemotherapy.
  • Treatment with letrozole was begun at 2.5 mg daily.
  • Serial computed tomography scans demonstrated marked tumor shrinkage; after 11 months of letrozole therapy, the tumor had shrunk to less than 25% of its original volume.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Mixed Tumor, Mullerian / drug therapy. Neoplasm Recurrence, Local / drug therapy. Nitriles / therapeutic use. Triazoles / therapeutic use. Uterine Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343224.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitriles; 0 / Triazoles; 7LKK855W8I / letrozole
  •  go-up   go-down


18. Sclafani F, Carnaghi C, Colombo P, Bozzarelli S, De Vincenzo F, Rimassa L, Giorgetti PL, Santoro A: Case report of acute aortic dissection during treatment with capecitabine for a late recurrence of breast cancer. Chemotherapy; 2010;56(3):203-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report of acute aortic dissection during treatment with capecitabine for a late recurrence of breast cancer.
  • BACKGROUND: Cardiovascular toxicity is amongst the most clinically relevant side effects of antitumoral treatments.
  • Moreover, the potential association between anticancer drugs and vascular damage is well known since chemotherapeutics, such as fluoropyrimidines, were introduced into clinical practice.
  • CASE: A 77-year-old woman treated with capecitabine for late recurrence of breast cancer developed life-threatening toxicity shortly after receiving the second cycle of therapy.
  • Although a history of cardiovascular disease was not reported, the imaging procedures performed upon admission to the hospital showed the unpredicted appearance of an acute aortic dissection of the abdominal aorta.
  • CONCLUSION: The absence of risk factors in the woman's history, timing of the dissection and associated life-threatening toxicities that developed, as well as the pathological findings are consistent with the vascular toxicity described in experimental models for fluoropyrimidines.
  • Combined with all these are circumstances supporting a probable cause-effect correlation between the chemotherapy and the dramatic vascular events that occurred.
  • [MeSH-major] Aneurysm, Dissecting / diagnosis. Aortic Aneurysm, Abdominal / diagnosis. Breast Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Aged. Capecitabine. Female. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20551636.001).
  • [ISSN] 1421-9794
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


19. Deffieux X, Morice P, Thoury A, Camatte S, Duvillard P, Castaigne D: Anatomy of pelvic and para-aortic nodal spread in patients with primary fallopian tube carcinoma. J Am Coll Surg; 2005 Jan;200(1):45-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Initial lymphadenectomy (without chemotherapy) was performed in 6 patients and in 13 patients lymphadenectomies were performed after chemotherapy at the time of second-look operation.
  • [MeSH-minor] Adult. Aged. Aorta, Abdominal. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Pelvis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15631919.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Nakamura T, Ota M, Narumiya K, Sato T, Ohki T, Yamamoto M, Mitsuhashi N: Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection. Ann Surg Oncol; 2008 Sep;15(9):2451-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection.
  • The aim of this study was to evaluate the outcome of intensive treatment for recurrent lymph node metastasis.
  • Multimodal treatment was performed in 41 patients: 19 patients underwent lymphadenectomy with adjuvant therapy, and 22 received definitive chemoradiotherapy and repeated chemotherapy.
  • The remaining 27 patients (40%) received chemotherapy or best supportive care.
  • RESULTS: Survival of the lymphadenectomy and the chemoradiotherapy groups was significantly better than that of the patients who received chemotherapy or best supportive care (P < .0001).
  • Although the location of lymph node metastasis did not influence survival significantly, seven patients with nodes around the abdominal aorta did not survive longer than 3 years.
  • The most common repeat recurrence pattern was organ metastasis after the treatment.
  • CONCLUSION: Multimodal treatment including lymphadenectomy and chemoradiotherapy could improve survival of the patients with lymph node recurrence of esophageal carcinoma after curative resection.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy. Esophagectomy. Lymph Node Excision. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18592318.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


21. Sato A, Shimada K, Nakamachi M, Ushio J, Yamamoto W, Kurihara M, Matsukawa M: Effectiveness of doxifluridine (5'-DFUR)/docetaxel against advanced/recurrent gastric cancer showing resistance to various anticancer drug regimens. Gastric Cancer; 2002;5(4):233-6
Hazardous Substances Data Bank. FLOXURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of doxifluridine (5'-DFUR)/docetaxel against advanced/recurrent gastric cancer showing resistance to various anticancer drug regimens.
  • A 58-year-old man was diagnosed as having type 3 gastric cancer (poorly differentiated adenocarcinoma).
  • He underwent total gastrectomy with splenectomy, as well as D3 dissection, and received postoperative chemotherapy combining oral uracil and futrafur (UFT) with cisplatin (CDDP), but results showed recurrence of multiple abdominal lymph node metastases around the aorta.
  • He therefore received various anticancer drug regimens (irinotecan [CPT-11]/CDDP; 1 M tegafur-0.4 M gimeracil-1 M oteracil potassium [TS-1], methotrexate (MTX)/5-fluorouracil); however, final results showed growth of lymph node metastasis and simultaneous worsening of his general condition.
  • Three courses of this regimen resulted in approximately 90% reduction of the abdominal lymph node size, disappearance of the right cervical lymph node metastasis, reductions of the levels of two tumor markers (carcinoembryonic antigen [CEA] and carbohydrate antigen [CA]19-9), and improvement of his general condition.
  • In the field of gastric cancer treatment, especially for patients showing multiple resistance to anticancer drugs, an effective therapy is critically needed.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Floxuridine / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Paclitaxel / administration & dosage. Paclitaxel / analogs & derivatives. Stomach Neoplasms / drug therapy. Taxoids
  • [MeSH-minor] Drug Resistance, Neoplasm. Fatal Outcome. Gastrectomy. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12491082.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 039LU44I5M / Floxuridine; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


22. Dubernard G, Morice P, Rey A, Camatte S, Pautier P, Lhommé C, Duvillard P, Castaigne D: Lymph node spread in stage III or IV primary peritoneal serous papillary carcinoma. Gynecol Oncol; 2005 Apr;97(1):136-41
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only 4 patients underwent this procedure as part of their initial surgery (before chemotherapy).
  • None of the patients with positive nodes developed recurrent disease in abdominal nodes.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aorta. Combined Modality Therapy. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Paclitaxel / administration & dosage. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790449.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


23. De Santis M, Ariosi P, Calò GF, Luppi G, Franchini M, Romagnoli R: [Antineoplastic perfusion with percutaneous stop-flow control in the treatment of advanced pelvic malignant neoplasms]. Radiol Med; 2000 Jul-Aug;100(1-2):56-61
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Antineoplastic perfusion with percutaneous stop-flow control in the treatment of advanced pelvic malignant neoplasms].
  • PURPOSE: The object of our study was to apply percutaneous stop-flow technique to advanced pelvic cancer in order to evaluate its feasibility, standardize the procedure and obtain preliminary results.
  • All treatments were performed under general anesthesia.
  • Blood flow was interrupted for a maximum of 20 min to limit tissue damage, especially of the anal sphincter.
  • Morphological response was evaluated by CT or MR scan performed prior to and 40 days after the treatment.
  • Death followed tumor progression in 6 cases; one patient died during the procedure and another one after 7 days, both secondary to pulmonary embolism.
  • Complications included intra-arterial rupture of the balloon in one case and a large inguinal hematoma 10 days after the treatment, requiring hospitalization.
  • CONCLUSIONS: This trial supports the feasibility of using the percutaneous stop-flow procedure in an angiography room setting; the stop-flow technique failed to permit the effective control of the tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chemotherapy, Cancer, Regional Perfusion / methods. Neoplasm Recurrence, Local / drug therapy. Pelvic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Anesthesia, General. Antibiotics, Antineoplastic / administration & dosage. Aorta, Abdominal / radiography. Cisplatin / administration & dosage. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Mitomycin / administration & dosage. Pelvis / pathology. Pelvis / radiography. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11109453.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] ITALY
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


24. Kuscu E, Oktem M, Haberal A, Erkanli S, Bilezikci B, Demirhan B: Management of advanced-stage primary carcinoma of the fallopian tube: case report and literature review. Eur J Gynaecol Oncol; 2003;24(6):557-60
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Total abdominal hysterectomy, bilateral salpingo-oophorectomy, appendectomy, omentectomy, pelvic and para-aortic lymph node dissection, and peritoneal washing were performed.
  • The definitive histopathological diagnosis was primary serous adenocarcinoma of the fallopian tube with six of 25 lymph node biopsies showing metastasis.
  • Six cycles of paclitaxel (175 mg/m2) plus cisplatin (75 mg/m2) combinatin chemotherapy were administered with 3-week intervals between cycles.
  • At the time of writing 12 months after the second-look laparotomy, she was still disease-free.
  • [MeSH-major] Cystadenocarcinoma, Serous / diagnosis. Fallopian Tube Neoplasms / diagnosis. Pelvic Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aorta, Thoracic. Appendectomy. Cisplatin / administration & dosage. Diagnosis, Differential. Fallopian Tubes / surgery. Female. Humans. Hysterectomy. Lymph Nodes / surgery. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Omentum / surgery. Ovariectomy. Paclitaxel / administration & dosage. Second-Look Surgery

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14658603.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 40
  •  go-up   go-down


25. Buchmann P: [Standard technique of oncologic colorectal surgery]. Swiss Surg; 2003;9(3):140-4
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ligation near to the aorta leads obligatory to lesions of the plexus hypogastricus.
  • Independent prognostic factors are the surgeon, the frequency of performing the procedure in the hospital concerned, the pT and N stage, the R-0 resection and according to American pathologists the pre-operative CEA titre.
  • What should be done in the distal 8 cm till the pelvic floor has not yet been clarified.
  • In the beginning of 2003, the pillars of the standard technique of oncological colo-rectal surgery are besides the orthograde intestinal flushing, the pre-operative low molecular Heparin and the antibiotic prophylaxis, the open or laparoscopic R-0 en bloc resection, the minimal safety distance in the low rectum of 1 cm, the ligature of the Arteria mesenterica inferior 2-3 cm distally to its origin from the aorta in case of left resection, respectively the Arteria ilio-colica at its origin from the Arteria mesenterica superior in case of right resection, the cytotoxic intestinal flushing in case of left resection and the flushing of the abdominal cavity as well as the port-site with Taurolin 0.5%.
  • In case of rectum-carcinoma uT3 or uN+, a neo-adjuvant radio-chemotherapy is administered and adjuvant chemotherapy is given by positive nodal colon-carcinoma.
  • [MeSH-minor] Animals. Colon / pathology. Colon / surgery. Humans. Neoplasm Staging. Practice Guidelines as Topic. Rectum / pathology. Rectum / surgery. Survival Analysis. Suture Techniques / standards

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12815836.001).
  • [ISSN] 1023-9332
  • [Journal-full-title] Swiss surgery = Schweizer Chirurgie = Chirurgie suisse = Chirurgia svizzera
  • [ISO-abbreviation] Swiss Surg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 23
  •  go-up   go-down


26. Hasuike Y, Takeda Y, Ueda S, Tujinaka T, Yoshida K: [A case report of primary hepatic carcinoid with lymph node metastasis--treatment of hepatic arterial infusion to post-reoperative liver and radiation to metastasis of para-aortic lymph nodes]. Gan To Kagaku Ryoho; 2002 Nov;29(12):2433-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of primary hepatic carcinoid with lymph node metastasis--treatment of hepatic arterial infusion to post-reoperative liver and radiation to metastasis of para-aortic lymph nodes].
  • She developed abdominal pain.
  • CT scans showed a low-density area in the lateral segment of the liver and lymph node swelling to the left of the abdominal aorta.
  • She underwent further liver resection and microwave coagulation therapy.
  • At that time, lymph node biopsy confirmed metastatic carcinoid.
  • We began hepatic arterial chemotherapy for the residual liver and radiation therapy for the para-aortic lymph nodes (total 45 Gy).
  • During chemotherapy, no recurrence was seen.
  • [MeSH-major] Carcinoid Tumor / therapy. Liver Neoplasms / therapy. Lymphatic Metastasis / pathology
  • [MeSH-minor] Combined Modality Therapy. Doxorubicin / administration & dosage. Electrocoagulation. Female. Fluorouracil / administration & dosage. Hepatectomy. Humans. Infusions, Intra-Arterial. Microwaves / therapeutic use. Middle Aged. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12484093.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil
  •  go-up   go-down


27. Vogl TJ, Zangos S, Eichler K, Balzer JO, Jacob U, Keilhauer R, Bauer RW: [Transarterial chemoperfusion of the pelvis--results in symptomatic locally recurrent tumors and lymph node metastases]. Rofo; 2007 Nov;179(11):1174-80
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Transarterielle Chemoperfusion des Beckens--Ergebnisse bei symptomatischen Rezidivtumoren und Lymphknotenmetastasen.
  • PURPOSE: To evaluate local transarterial chemoperfusion (TACP) of therapy-resistant, locally recurrent malignant tumors and lymph node metastases in the pelvis with respect to clinical response, tumor response and survival.
  • Depending on the tumor location and vascularization, a fluoroscopy catheter was placed either in the abdominal aorta or internal pelvic artery.
  • In the case of clinical and radiological progression, therapy was stopped and the patient was referred to the hospital's tumor board.
  • In the case of radiological response and clinical progression or clinical response and radiological progression, therapy was continued.
  • Therapy could be stopped by the patient at any time.
  • RESULTS: Treatment was tolerated well by all patients.
  • CONCLUSION: Since tumor-related complaints were improved in 54% of the cases and control of tumor growth (PR+SD) was achieved in 67% of the cases, TACP for recurrent pelvic malignancies should be considered as a palliative oncological treatment option.
  • [MeSH-major] Lymphatic Metastasis / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Arteries. Drug Resistance, Neoplasm. Female. Humans. Injections, Intra-Arterial / adverse effects. Middle Aged. Mitomycin / administration & dosage. Mitomycin / therapeutic use. Perfusion / adverse effects. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17805998.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin
  •  go-up   go-down


28. Cao Y, Xia QH, Meng H, Zhong AP: Pharmacological effects of serum containing chinese medicine Bushen Huayu Jiedu Compound Recipe in lung cancer drug-resistance cells. Chin J Integr Med; 2008 Mar;14(1):46-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacological effects of serum containing chinese medicine Bushen Huayu Jiedu Compound Recipe in lung cancer drug-resistance cells.
  • OBJECTIVE: To explore the pharmacologic effects of Chinese medicine Bushen Huayu Jiedu Compound Recipe (BSHYJDR) in drug-resistance cells of lung cancer.
  • Serum from the abdominal aorta was taken to observe the effect of drug-serum on cisplatin (DDP) concentration, free Ca2+ concentration and the expression of lung drug-resistance protein LRP-56 in A549/DDP cells.
  • RESULTS: Compared with the drug-resistance group, the intracellular DDP concentration in the group taking a high dose and the normal group of Chinese medicine showed significant difference (P<0.05), while no significant difference was found in the low-dose group (P>0.05).
  • Compared with the drug-resistance group, the Ca2+ concentration in cells and the expression of LRP in lung cancer drug-resistance cells A549/DDP of the high-dose group, the low-dose group and the normal group of Chinese medicine were significantly different (all P<0.01), the LRP expression of the normal group was obviously higher than that of the drug-resistance group (P<0.05).
  • CONCLUSION: It was indicated that serum containing Chinese medicine BSHYJDR in the tumor-bearing mice and the normal mice had certainly different, tumor-bearing mice serum containing could improve drug concentration in lung cancer drug-resistance cells, prevent the inflow and release of Ca2+, and inhibit the expression of the drug-resistance gene in the lung cancer drug-resistance cells, which might be the mechanism of BSHYJDR in enhancing the efficacy in reversing and inhibiting tumor.
  • [MeSH-major] Lung Neoplasms / drug therapy. Medicine, Chinese Traditional
  • [MeSH-minor] Animals. Calcium / metabolism. Cell Line, Tumor. Cisplatin / pharmacology. Drug Resistance, Neoplasm. Humans. Mice. Vault Ribonucleoprotein Particles / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4C):3077-80 [9713513.001]
  • [Cites] Int J Cancer. 2000 Apr 1;86(1):95-100 [10728601.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Oct 13;215(2):566-71 [7487993.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1475-9 [7680954.001]
  • [Cites] Int J Cancer. 2000 Oct 15;88(2):293-300 [11004683.001]
  • [Cites] Eur J Cancer. 1996 Jun;32A(6):945-57 [8763335.001]
  • [Cites] Zhonghua Jie He He Hu Xi Za Zhi. 2001 Aug;24(8):458-60 [11718033.001]
  • [Cites] Br J Cancer. 1991 Dec;64(6):1011-8 [1684906.001]
  • (PMID = 18219453.001).
  • [ISSN] 1672-0415
  • [Journal-full-title] Chinese journal of integrative medicine
  • [ISO-abbreviation] Chin J Integr Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; Q20Q21Q62J / Cisplatin; SY7Q814VUP / Calcium
  •  go-up   go-down


29. Kohya N, Hashiguchi K, Yakabe T, Miyoshi A, Ohtsuka T, Kitahara K, Miyazaki K: [A case of unresectable hilar bile duct cancer responding to chemo-radiotherapy by gemcitabine]. Gan To Kagaku Ryoho; 2009 Oct;36(10):1753-5
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Abdominal CT scan showed a dilatation of the intra-hepatic bile duct and a tumor around hilar bile duct.
  • We diagnosed it as hilar bile duct carcinoma, and although we operated it was unresectable because of the metastasis of a para-aorta lymph node and duodenal invasion.
  • We started chemo-radiotherapy with a total dose of 45 Gy and gemcitabine.
  • The tumor and para-aorta lymph node were remarkably decreased, and tumor marker CA 19-9 was also decreased to within the normal range.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / radiotherapy. Deoxycytidine / analogs & derivatives
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Combined Modality Therapy. Duodenal Neoplasms / drug therapy. Duodenal Neoplasms / radiography. Duodenal Neoplasms / secondary. Fatal Outcome. Female. Humans. Lymphatic Metastasis. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838042.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down






Advertisement